EN DE
Watch Avantor Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Avantor Inc (AVTR) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Avantor Inc stock $9.32, price $15.47, that is 39.8% below the price, quality 49 out of 100. Rating: strongly overvalued. Calculated from audited financials with 8 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

AI Avantor Inc logo Some data Nov 4, 2026

Avantor Inc

AVTR · US
Very expensive, weak quality

Our calculation puts a fair price 40% below what the stock costs today.

Generates free cash flow
Upbeat coverage
Quality 49/100
Thin margins · 5.1% net margin (TTM) · excl. goodwill write-downs +16.9%
Moderate debt
Some data
Profit last quarter 37% below a year ago.
Fair value $9.32 · Strongly overvalued
Weak Growth (revenue 5y +0.5 %/yr in USD)
Trails peers (2/12)
Narrow moat 32/100

Risks from the AI analysis

🚩Rivals like Thermo Fisher pressuring prices and share🚩Dependence on limited suppliers for key materials
Watch Avantor Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$44.01 $7.41 Fair Value $9.32 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.

How to read this chart

60‑month range $7.41 – $44.01 · fair‑value band $3.25 – $17.61 · the $15.47 price screens above the $9.32 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.

Follow Avantor in your weekly email

Every Wednesday you see whether Avantor is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa.

Show moreShow less

The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, and fluid handling tips.

It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, peristaltic pumps, and critical environment supplies.

In addition, the company offers services and specialty procurements comprising onsite lab and production, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services.

Further, it provides scientific research support services, such as DNA extraction, bioreactor servicing, clinical and biorepository, compound management, cleanroom control, monitoring, maintenance, and sanitization services.

The company was founded in 1904 and is headquartered in Radnor, Pennsylvania.

Stock analysis

Avantor Inc (AVTR) currently trades at $15.47, while our model-based Fair Value estimate is $9.32, 40% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of $13.19 per share, and 2 of the 8 models we run sit above the $15.47 price.

Bear case: the Multiples group reads lowest at $4.21, and 6 of the 8 models stay below the price. Data coverage for this calculation is medium.

Scenario range: $3.25 (bear) to $17.61 (bull), the price of $15.47 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Avantor Inc reported revenue of $6.6B in FY2025 versus $7.4B in FY2021, a compound −3.0%/yr. Reported net income was −$530M in FY2025.

Key figures

Market cap $10.5B Large · P/E ratio 30.9 · P/S ratio 1.58 · EPS (TTM) $0.5000 · Net margin 5.1% · Return on equity 5.9% · Return on assets (EBIT) 5.5% (5-year average) · Operating margin 8.2%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).

What moves the price

The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.

The share trades about 11% below its 52-week high and 109% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −44% fair-value upside, at −40%, AVTR screens cheaper than that median.

Fair Value models

Bear $3.25 Fair Value $9.32 Bull $17.61
Price $15.47 · Downside -39.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($0.4288 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $7.26 $18.71 $39.55 74
Growth DCF $7.04 $17.17 $34.83 73
5Y Revenue Exit $3.25 $9.32 $17.61 68
All 8 models by family
DCF Models
FCF DCF $7.26 $18.71 $39.55 74
5Y Revenue Exit $3.25 $9.32 $17.61 68
5Y EBITDA Exit $0.3000 $3.00 $6.21 67
10Y Revenue Exit $4.24 $10.58 $20.50 62
10Y EBITDA Exit $2.49 $5.87 $10.63 65
Multiples
EV/Revenue $1.36 $4.21 $7.06 49
Growth DCF
Growth DCF $7.04 $17.17 $34.83 73
Rev-Margin DCF $3.25 $9.20 $17.22 68

Open the full fair value analysis →

Quality Score breakdown

Overall quality 49/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 14
How much profit the company makes from its sales and capital
Quality Growth 19
Are margins and returns getting better?
Cashflow 52
Do the profits arrive as real cash?
Financial strength 45
Debt, balance sheet and risk of trouble
Investment 92
Does it invest with discipline instead of growing at any price?
Low Volatility 52
How calm the share price moves, does not count
Price momentum 79
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 76
Distance to the 52-week high, does not count
New shares 84
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

  • BuyGregory T LucierDirector2× since Feb 19, 2026: 60,000 shares, avg. $9.02$541,200May 8, 2026
  • BuySimon DingemansDirector25,000 shares at $8.14$203,500May 1, 2026
  • BuySanjeev K MehraDirector2× since Dec 5, 2025: 475,000 shares, avg. $10.28$4.9MMar 10, 2026
  • BuyGregory L SummeDirector100,000 shares at $9.40$940,000Feb 12, 2026
  • BuyEmmanuel LignerPresident and CEO, Director87,500 shares at $11.35$993,125Nov 17, 2025

Plus 8 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−3.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.5%
Start year 2020 (pandemic). Over 10 years: +26.3% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+26.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
11.1% (2020) → −3.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+14.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+2.5%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +11.6% a year for the price and +0.1% for the forecasts.
Forecast 2026 (sales)+1.8%
Forecast 2027 (sales)+2.8%
Projected 2028 (sales)+2.7%
Projected 2029 (sales)+2.6%
Projected 2030 (sales)+2.5%

AVTR screens overvalued: fair value 40% below the price. Compare with Intuitive Surgical, Inc →

Recent news

News mood ⓘNews mood, the average tone of recent news (96 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
Note from the team Oct 11, 2026
AI conclusion: Recurring revenue from mission-critical consumables and services provides stability, yet weak profitability and a large goodwill impairment remain the key limitations.
Main risk: Larger competitors such as Thermo Fisher Scientific with greater scale in instruments and distribution could capture more lab and bioprocessing customers or force lower prices on consumables and services.
Bull case: By deepening partnerships for intelligent consumables and leveraging its distribution network Avantor could retain customers and expand in personalized medicine despite rival scale.
Bear case: If larger rivals continue gaining share through integrated offerings and supply issues persist Avantor might lose recurring revenue streams in lab distribution and bioprocessing.
Avantor delivers mission-critical consumables and services to biopharma and lab customers, creating recurring revenue that holds up better than pure research spending. A new CFO joined in September just as the bioproduction segment shows early order recovery while overall organic growth remains modest. Will tighter execution under fresh leadership lift margins enough to justify current valuations, or will lingering integration issues from portfolio changes keep results muted?
Join the discussion →

Compare Avantor Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 181 stocks

Beats the industry median on 2/12 measures
Overall it trails its industry peers.
Valuation
Quality Score 49 · Below median
Fair Value upside −39.8% · Below median
Profitability
Return on equity (12 months) 5.9% · Below median
Return on assets −4.5% · Bottom 25%
Net margin (12 months) 5.1% · Below median
Operating margin (12 months) 8.2% · Below median
Growth and dividend
Revenue growth (quarter YoY) 4.6% · Below median
Balance sheet
Debt / equity 0.70× · Highest 25%

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/E (12 months) 30.9× · Pricier than median
P/B 1.88× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 1.58× · Cheaper than median
Price / free cash flow (fiscal year) 21.2× · Cheaper than median
EV/EBITDA 14.8× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 25
FUTURE (revenue growth)23 · sector 40
PAST (return on equity)24 · sector 30
HEALTH (low debt)65 · sector 96
DIVIDEND (yield)0 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Solventum Corporation SOLV $90.38 $131.27 +45% vs AVTR
EssilorLuxottica Société anonyme EL €193.80 €196.22 +1% vs AVTR
Intuitive Surgical, Inc ISRG $452.80 $353.90 −22% vs AVTR
Medline Inc MDLN $39.64 $28.59 −28% vs AVTR
Alcon Inc ALC CHF 61.30 CHF 34.06 −44% vs AVTR
Becton, Dickinson and Company BDX $211.88 $97.80 −54% vs AVTR
Straumann Holding STMN CHF 104.50 CHF 45.50 −56% vs AVTR
West Pharmaceutical Services, Inc WST $399.81 $139.22 −65% vs AVTR
Sartorius Stedim Biotech S.A DIM €225.80 €54.82 −76% vs AVTR
Sartorius Aktiengesellschaft SRT €227.00 €42.50 −81% vs AVTR

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Avantor Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Avantor Inc Fair Value". https://www.fairvalue-calculator.com/stock/AVTR

Frequently asked questions

Is Avantor Inc (AVTR) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of $9.32 versus a price of $15.47, about 40% lower (overvalued).
What is the fair value of AVTR?
Our model-based fair value for Avantor Inc is $9.32 (as of Nov 4, 2026), built from audited fundamentals. The current price: $15.47.
What is the quality score of AVTR?
Avantor Inc has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Avantor Inc (AVTR)?
Our model-based price target is the fair value of $9.32 (as of Nov 4, 2026) from 8 valuation models. Cautious scenario $3.25, optimistic scenario $17.61. It is a calculation from audited fundamentals, not an analyst target.
What is the Avantor Inc stock forecast for 2026?
Our models put fair value at $9.32, about 40% lower versus a price of $15.47 (overvalued). Cautious scenario $3.25, optimistic scenario $17.61. The calculation is refreshed regularly with new filings.
What is the revenue of Avantor Inc (AVTR)?
Avantor Inc reported trailing-twelve-month revenue of about $6.6B (latest available figure, as of Nov 4, 2026).
What growth is priced into Avantor Inc (AVTR)?
For today's price to be fair in a discounted-cash-flow model, Avantor Inc would have to grow free cash flow by +14.3 % per year for five years (discount rate 9.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +0.5 % per year. As of Nov 4, 2026.
What discount rate (WACC) does the fair value of AVTR use?
Our models discount Avantor Inc at 9.1 %: a base by market capitalisation (large), damped by beta 0.94, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Avantor Inc that is +14.3 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.1 %) and the same formula as our fair value.
How much growth has Avantor Inc (AVTR) delivered so far?
Over the past 5 years revenue at Avantor Inc grew +0.5 % a year. The price currently implies free-cash-flow growth of +14.3 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Avantor Inc (AVTR) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Avantor Inc (+14.3 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Avantor Inc (AVTR)?
The free-cash-flow yield on the price is 4.72 %: that much free cash flow Avantor Inc produces per unit of market value. When it exceeds the discount rate of our models (9.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Avantor Inc (AVTR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Avantor Inc it is $9.32 per share (as of Nov 4, 2026), against a price of $15.47. It is the blended result of 8 valuation models in 3 families (DCF Models, Multiples, Growth DCF).
Is Avantor Inc stock overvalued or undervalued in 2026?
As of Nov 4, 2026, AVTR trades above its calculated fair value: price $15.47, fair value $9.32, a gap of about −40% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of AVTR?
No. The price is what the market pays today ($15.47); the fair value is what the company's own numbers justify ($9.32). For Avantor Inc the two are $6.15 per share apart. That gap is exactly why we show both numbers side by side.
How much is Avantor Inc worth?
The market values Avantor Inc at about $10.5B (market capitalisation, as of Nov 4, 2026). Per share that is $15.47; our models calculate a fair value of $9.32 per share.
What do the bullish and bearish scenarios say about AVTR?
Our models span a range for Avantor Inc: cautious scenario $3.25, base $9.32, optimistic $17.61 per share (as of Nov 4, 2026, price $15.47). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of AVTR?
Avantor Inc trades at a price-to-earnings ratio of 30.9 (as of Nov 4, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $9.32 is built from several models across several years. Median P/E at fiscal year-end, 6 fiscal years (2019 to 2024), reported earnings: 46.2. Other multiples: P/B 1.9, P/S 1.6, EV/EBITDA 14.8.
How solid is the balance sheet of Avantor Inc (AVTR)?
Balance-sheet figures for Avantor Inc (as of Nov 4, 2026): return on equity 5.9%, debt of 0.70 per unit of equity. They feed the Quality Score of 49/100, which measures business quality independently of the share price.
How far is AVTR from its 52-week high?
Avantor Inc trades at $15.47, about 11% below its 52-week high of $17.29 and 109% above the low of $7.41 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $9.32 is for.
Which stocks are comparable to Avantor Inc?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Avantor Inc stock attractive at the current price?
The data as of Nov 4, 2026: price $15.47, calculated fair value $9.32 (−40%), Quality Score 49/100, from 8 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of AVTR calculated?
We run Avantor Inc through 8 models from 3 families: DCF Models, Multiples, Growth DCF. Every model gets the same audited fundamentals; the fair value of $9.32 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Avantor Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Avantor Inc (AVTR)?
The closing price on Nov 6, 2026 was $15.47. Our model-based fair value is $9.32, about 40% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Avantor Inc right now?
Weak quality (49/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide ($3.25 to $17.61). The outcome hinges heavily on assumptions, so read the point estimate with caution.

Key figures of Avantor Inc

How large is the market capitalisation of Avantor Inc (AVTR)?
The market capitalisation of Avantor Inc is $10.5B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Avantor Inc (AVTR)?
The price-to-sales ratio of Avantor Inc is 1.58 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Avantor Inc (AVTR)?
Earnings per share at Avantor Inc are $0.5000 (price ÷ EPS = P/E 30.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Avantor Inc (AVTR)?
The net margin of Avantor Inc is 5.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Avantor Inc (AVTR)?
The return on equity (ROE) of Avantor Inc is 5.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Avantor Inc (AVTR)?
On an EBIT basis the return on assets of Avantor Inc is 5.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Avantor Inc (AVTR)?
The operating margin of Avantor Inc is 8.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Avantor Inc (AVTR)?
Revenue at Avantor Inc is growing +4.6% versus a year earlier (3y avg +10.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Avantor Inc (AVTR)?
Earnings per share at Avantor Inc are growing −37.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Avantor Inc (AVTR) carry?
The net debt of Avantor Inc is $3.6B (fiscal year 2025, ≈ 7.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Avantor Inc in the live analysis

One click puts Avantor Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.